Back to Journals » Drug Design, Development and Therapy

SJR OA
CiteScore
Impact Factor

Drug Design, Development and Therapy


      

ISSN: 1177-8881

Editor-in-Chief: Prof. Dr. Frank Boeckler

An international, peer-reviewed, open access journal that spans the spectrum of drug design and development through to clinical applications. The journal is characterized by the rapid reporting of application notes, reviews, original research and clinical studies in all therapeutic areas. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines will be a feature of the journal. 

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE).

Articles:

Latest articles:

- 5 records -

Original Research

6-Methoxyflavone and Donepezil Behavioral Plus Neurochemical Correlates in Reversing Chronic Ethanol and Withdrawal Induced Cognitive Impairment

Arif M, Rauf K, Rehman NU, Tokhi A, Ikram M, Sewell RD

Drug Design, Development and Therapy 2022, 16:1573-1593

Published Date: 28 May 2022

Original Research

Ropivacaine with Dexmedetomidine or Dexamethasone in a Thoracic Paravertebral Nerve Block Combined with an Erector Spinae Plane Block for Thoracoscopic Lobectomy Analgesia: A Randomized Controlled Trial

Yang J, Zhao M, Zhang XR, Wang XR, Wang ZH, Feng XY, Lei YJ, Zhang JW

Drug Design, Development and Therapy 2022, 16:1561-1571

Published Date: 26 May 2022

Review

Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP

Wang L

Drug Design, Development and Therapy 2022, 16:1547-1559

Published Date: 25 May 2022

Original Research

Reduced the Food Effect and Enhanced the Oral Bioavailability of Ivacaftor by Self-Nanoemulsifying Drug Delivery System (SNEDDS) Using a New Oil Phase

Miao Y, Zhao S, Zuo J, Sun J, Wang J

Drug Design, Development and Therapy 2022, 16:1531-1546

Published Date: 23 May 2022

Original Research

“PFH/AGM-CBA/HSV-TK/LIPOSOME-Affibody”: Novel Targeted Nano Ultrasound Contrast Agents for Ultrasound Imaging and Inhibited the Growth of ErbB2-Overexpressing Gastric Cancer Cells

Zhou H, Liu H, Zhang Y, Xin Y, Huang C, Li M, Zhao X, Ding P, Liu Z

Drug Design, Development and Therapy 2022, 16:1515-1530

Published Date: 18 May 2022

 

Read more articles